Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study

2007; SAGE Publishing; Volume: 16; Issue: 7 Linguagem: Inglês

10.1177/0961203307079300

1477-0962

Clóvis A. Silva, Maria Odete Esteves Hilário, M.V. Febrônio, Sheila Knupp Feitosa de Oliveira, Maria Teresa Terreri, Silvana Sacchetti, Flávio Sztajnbok, Roberto Marini, Maria Vitória Quintero, Blanca Bica, Rosa Maria Rodrigues Pereira, Eloísa Bonfá, Virgínia Paes Leme Ferriani, Teresa Cristina Martins Vicente Robazzi, Cláudia Saad Magalhães,

Eosinophilic Disorders and Syndromes

We evaluated the prevalence and clinical associations of amenorrhea in 298 female juvenile systemic lupus erythematosus (JSLE) patients (ACR criteria) followed in 12 Brazilian Paediatric Rheumatology centres. Amenorrhea was observed in 35 patients (11.7%) with a mean duration of 7.2 ± 3.6 months. The hormones were performed in 32/35 patients and none of them had FSH and LH levels above and estradiol below the normal range according to pubertal changes. JSLE patients with amenorrhea were younger (15.04 ± 2.5 versus 17.8 ± 3.1 years; P = 0.001), and had a shorter period of time between menarche and current age (3.4 ± 2.9 versus 6.7 ± 5.4 years; P = 0.001). Interestingly, the frequency, cumulative dose, number of pulses and duration of intravenous cyclophosphamide treatment were alike in patients with and without amenorrhea ( P > 0.05). In contrast, patients with amenorrhea had significantly higher SLEDAI ( P = 0.01) and SLICC/ACR-DI ( P = 0.024) scores compared to those without this condition. Independent risk factors identified by multivariate analysis were higher SLEDAI (OR = 1.059; CI = 1.004—1.116; P = 0.034) and SLICC/ACR-DI (OR = 2.125; IC = 1.373—3.291; P = 0.001) scores. Our data suggest that in spite of immunosuppressive therapy, JSLE patients have an adequate ovarian follicular reserve and amenorrhea is particularly associated with disease activity and damage. Lupus (2007) 16, 531—536.